RARE
Ultragenyx Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.73
+5.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 716.9M | 673.0M | 560.2M | 434.2M | 363.3M |
| Cost of Revenue | 121.0M | 109.0M | 76.7M | 45.2M | 28.3M |
| Gross Profit | 595.9M | 564.0M | 483.5M | 389.0M | 335.0M |
| Operating Expenses | |||||
| R&D Expense | 773.2M | 750.0M | 697.9M | 648.4M | 705.8M |
| SG&A Expense | 351.6M | 349.0M | 321.6M | 309.8M | 278.1M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.1B | 1.0B | 958.2M | 983.9M |
| Cost and Expenses | 1.2B | 1.2B | 1.1B | 1.0B | 1.0B |
| Operating Income (EBIT) | (528.9M) | (535.0M) | (536.0M) | (569.2M) | (648.9M) |
| Non-Operating | |||||
| Interest Income | 23.4M | 25.0M | 36.5M | 26.7M | 11.1M |
| Interest Expense | 76.1M | 62.0M | 63.0M | 66.0M | 43.0M |
| Net Interest Income | (52.8M) | (37.0M) | (26.5M) | (39.3M) | (31.9M) |
| Other Non-Op Income/Expense | (53.6M) | (36.0M) | (31.6M) | (39.3M) | (52.8M) |
| Non-Operating Income (excl Interest) | (22.5M) | (26.0M) | (31.4M) | (26.7M) | 9.8M |
| EBT (Pre-Tax Income) | (582.5M) | (571.0M) | (567.6M) | (608.5M) | (701.7M) |
| Income Tax Expense | 3.9M | 4.0M | 1.6M | (1.8M) | 5.7M |
| Bottom Line | |||||
| Net Income | (586.4M) | (575.0M) | (569.2M) | (606.6M) | (707.4M) |
| Earnings from Cont. Ops | (586.4M) | (575.0M) | (569.2M) | (606.6M) | (707.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (586.4M) | (575.0M) | (569.2M) | (606.6M) | (707.4M) |
| Per Share | |||||
| Basic EPS | ($5.84) | ($5.83) | ($6.29) | ($8.25) | ($10.12) |
| Diluted EPS | ($5.84) | ($5.83) | ($6.29) | ($8.25) | ($10.12) |
| Revenue Per Share | $7.04 | $6.83 | $6.19 | $5.90 | $5.20 |
| Shares | |||||
| Basic Shares Outstanding | 101.9M | 98.6M | 90.5M | 73.5M | 69.9M |
| Diluted Shares Outstanding | 101.9M | 98.6M | 90.5M | 73.5M | 69.9M |
| Profitability Metrics | |||||
| EBITDA | (473.0M) | (474.0M) | (469.0M) | (516.5M) | (640.5M) |
| D&A | 33.4M | 35.0M | 35.5M | 26.0M | 18.2M |
| EBIT | (506.4M) | (509.0M) | (504.5M) | (542.5M) | (658.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026